In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia
In order to determine the potential role that various antifungal agents might have in the management of cryptococcosis in tropical areas, the in vitro susceptibility of Cryptococcus neoformans isolates from Africa ( n=52) and Cambodia ( n=110) to three antifungal agents (amphotericin B, fluconazole and voriconazole) were compared using the E-test method. The results of this study (i) confirm the value of the E-test for testing the in vitro susceptibility of C. neoformans towards voriconazole; (ii) provide the first evidence demonstrating good activity of amphotericin B, fluconazole and voriconazole against Cambodian isolates; and (iii) show there are differences in susceptibility between African and Asian C. neoformans isolates, with Cambodian isolates appearing less susceptible to the agents tested but with amphotericin B maintaining good activity.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2004 |
|---|---|
| Erschienen: |
2004 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 23(2004), 6 vom: 10. Juni, Seite 506-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chandenier, J [VerfasserIn] |
|---|
| Themen: |
7XU7A7DROE |
|---|
| Anmerkungen: |
Date Completed 17.08.2004 Date Revised 13.11.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM148315763 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM148315763 | ||
| 003 | DE-627 | ||
| 005 | 20231223045320.0 | ||
| 007 | tu | ||
| 008 | 231223s2004 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0495.xml |
| 035 | |a (DE-627)NLM148315763 | ||
| 035 | |a (NLM)15141336 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chandenier, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2004 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In order to determine the potential role that various antifungal agents might have in the management of cryptococcosis in tropical areas, the in vitro susceptibility of Cryptococcus neoformans isolates from Africa ( n=52) and Cambodia ( n=110) to three antifungal agents (amphotericin B, fluconazole and voriconazole) were compared using the E-test method. The results of this study (i) confirm the value of the E-test for testing the in vitro susceptibility of C. neoformans towards voriconazole; (ii) provide the first evidence demonstrating good activity of amphotericin B, fluconazole and voriconazole against Cambodian isolates; and (iii) show there are differences in susceptibility between African and Asian C. neoformans isolates, with Cambodian isolates appearing less susceptible to the agents tested but with amphotericin B maintaining good activity | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a Amphotericin B |2 NLM | |
| 650 | 7 | |a 7XU7A7DROE |2 NLM | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a Voriconazole |2 NLM | |
| 650 | 7 | |a JFU09I87TR |2 NLM | |
| 700 | 1 | |a Adou-Bryn, K D |e verfasserin |4 aut | |
| 700 | 1 | |a Douchet, C |e verfasserin |4 aut | |
| 700 | 1 | |a Sar, B |e verfasserin |4 aut | |
| 700 | 1 | |a Kombila, M |e verfasserin |4 aut | |
| 700 | 1 | |a Swinne, D |e verfasserin |4 aut | |
| 700 | 1 | |a Thérizol-Ferly, M |e verfasserin |4 aut | |
| 700 | 1 | |a Buisson, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Richard-Lenoble, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 23(2004), 6 vom: 10. Juni, Seite 506-8 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2004 |g number:6 |g day:10 |g month:06 |g pages:506-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2004 |e 6 |b 10 |c 06 |h 506-8 | ||